TNFα-Based Isolated Perfusion for Limb-Threatening Soft Tissue Sarcomas: State of the Art and Future Trends

Journal of Immunotherapy

Volumn 26, Issue 4, 2003, Pages 291-300

  Rossi, Carlo Riccardo ^a   Mocellin, Simone ^a   Pilati, Pierluigi ^a   Foletto, Mirto ^a   Nitti, Donato ^a   Lise, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Hyperthermic isolated limb perfusion; Soft tissue sarcoma; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; ALBUMIN TC 99M; DOPAMINE; DOXORUBICIN; GAMMA INTERFERON; HYPERTENSIVE AGENT; IODINE 131; MELPHALAN;

HUMAN; HYPERTHERMIC THERAPY; METABOLISM; PATHOLOGY; PERFUSION; PROGNOSIS; REGIONAL PERFUSION; REVIEW; SARCOMA; SOFT TISSUE TUMOR; TIME; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD OXYGENATION; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURGERY; CAPILLARY LEAK SYNDROME; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; FLOW RATE; FLUID THERAPY; HEPARINIZATION; HIGH TEMPERATURE; HYPERTHERMIC ISOLATED LIMB PERFUSION; IMMUNOSTIMULATION; LIFE EXPECTANCY; LIMB AMPUTATION; LYMPHATIC DRAINAGE; NERVE DECOMPRESSION; NEURALGIA; NEURITIS; PARESIS; PATHOPHYSIOLOGY; PERONEUS NERVE; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SEPTIC SHOCK; SOFT TISSUE SARCOMA; SURGICAL MORTALITY; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT INDICATION; TUMOR VASCULARIZATION; URINE VOLUME;

CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; HYPERTHERMIA, INDUCED; PERFUSION; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037829446     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200307000-00001     Document Type: Review

References (121)

1. American Cancer Society. Cancer: facts and figures. American Cancer Society, 1995.
2. Pollock RE, Karnell LH, Menck HR, et al. The National Cancer Data Base report on soft tissue sarcoma. Cancer. 1996; 78:2247-2257.
3. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996; 224:756-765.
4. Zornig C, Weh HJ, Krull A, et al. Soft tissue sarcomas of the extremities and trunk in the adult. Report of 124 cases. Langenbecks Arch Chir. 1992; 377:28-33.
5. Morton DL, Eilber FR, Weisenburger TH, et al. Limb salvage using preoperative intraarterial Adriamycin and radiation therapy for extremity soft tissue sarcomas. Aust NZ J Surg. 1978; 48:56-59.
6. Spiro IJ, Rosenberg AE, Springfield D, et al. Combined surgery and radiation therapy for limb preservation in soft tissue sarcoma of the extremity: the Massachusetts General Hospital experience. Cancer Invest. 1995; 13:86-95.
7. Billingsley KG, Lewis JJ, Leung DH, et al. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999; 85:389-395.
8. Williard WC, Collin C, Casper ES, et al. The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surg Gynecol Obstet. 1992; 175:389-396.
9. Spiro IJ, Gebhardt MC, Jennings LC, et al. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol. 1997; 24:540-546.
10. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol. 1992; 10:1317-1329.
11. Williard WC, Hajdu SI, Casper ES, et al. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg. 1992; 215:269-275.
12. Rossi CR, Foletto M, Alessio S, et al. Limb-sparing treatment for soft tissue sarcomas: influence of prognostic factors. J Surg Oncol. 1996; 63:3-8.
13. Tanabe KK, Pollock RE, Ellis LM, et al. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer. 1994; 73:1652-1659.
14. Stotter AT, A'Hern RP, Fisher C, et al. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer. 1990; 65:1119-1129.
15. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996; 14:859-868.
16. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998; 16:197-203.
17. Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer. 1994; 6:746-751.
18. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19:1238-1247.
19. Karakousis CP, Proimakis C, Walsh DL. Primary soft tissue sarcoma of the extremities in adults. Br J Surg. 1995; 82:1208-1212.
20. Keus RB, Rutgers EJ, Ho GH, et al. Limb-sparing therapy of extremity soft tissue sarcomas: treatment outcome and long-term functional results. Eur J Cancer. 1994; 10:1459-1463.
21. Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997; 79:1129-1137.
22. Pitcher ME, Ramanathan RC, Fish S, et al. Outcome of treatment for limb and limb girdle sarcomas at the Royal Marsden Hospital. Eur J Surg Oncol. 2000; 26:548-551.
23. Trovik CS, Gustafson P, Bauer HC, et al. Consequences of local recurrence of soft tissue sarcoma: 205 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2000; 71:488-495.
24. Toffoli G, Frustaci S, Tumiotto L, et al. Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol. 1992; 3:63-69.
25. Rouesse JG, Friedman S, Sevin DM, et al. Preoperative induction chemotherapy in the treatment of locally advanced soft tissue sarcomas. Cancer. 1987; 60:296-300.
26. Pisters PW, Patel SR, Varma DG, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol. 1997; 15:3481-3487.
27. Hew L, Kandel R, Davis A, et al. Histological necrosis in soft tissue sarcoma following preoperative irradiation. J Surg Oncol. 1994; 57:111-114.
28. Suit HD, Proppe KH, Mankin HJ, et al. Preoperative radiation therapy for sarcoma of soft tissue. Cancer. 1981; 47:2269-2274.
29. Brant TA, Parsons JT, Marcus Jr, RB et al. Preoperative irradiation for soft tissue sarcomas of the trunk and extremities in adults. Int J Radiat Oncol Biol Phys. 1990; 19:899-906.
30. De Paoli A, Bertola G, Boz G, et al. Radiation therapy and conservative surgery for soft tissue sarcomas of the extremities, torso and head and neck. Ann Oncol. 1992; 3(Suppl 2):S97-101.
31. Cheng EY, Dusenbery KE, Winters MR, et al. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol. 1996; 61:90-99.
32. Huth JF, Eilber FR. Preoperative intra-arterial chemotherapy. Cancer Treat Res. 1989; 44:103-110.
33. Soulen MC, Weissmann JR, Sullivan KL, et al. Intraarterial chemotherapy with limb-sparing resection of large soft-tissue sarcomas of the extremities. J Vasc Interv Radiol. 1992; 3:659-663.
34. Bezwada HP, Granick MS, Long CD, et al. Soft-tissue complications of intra-arterial chemotherapy for extremity sarcomas. Ann Plast Surg. 1998; 40:382-387.
35. Azzarelli A, Quagliuolo V, Fissi S, et al. Intra-arterial induction chemotherapy for soft tissue sarcomas. Ann Oncol. 1992; 3(Suppl 2):S67-S70.
36. Rahoty P, Konya A. Results of preoperative neoadjuvant chemotherapy and surgery in the management of patients with soft tissue sarcoma. Eur J Surg Oncol. 1993; 19:641-645.
37. Temple WJ, Temple CL, Arthur K, et al. Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas. Ann Surg Oncol. 1997; 4:586-590.
38. Goodnight Jr, JE Bargar WL, Voegeli T, et al. Limb-sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy. Am J Surg. 1985; 150:109-113.
39. Wanebo HJ, Temple WJ, Popp MB, et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer. 1995; 75:2299-2306.
40. Nijhuis PH, Pras E, Sleijfer DT, et al. Long-term results of preoperative intra-arterial doxorubicin combined with neoadjuvant radiotherapy, followed by extensive surgical resection for locally advanced soft tissue sarcomas of the extremities. Radiother Oncol. 1999; 51:15-19.
41. Giuliano AE, Eilber FR, Morton DL. The management of locally recurrent soft-tissue sarcoma. Ann Surg. 1982; 196:87-91.
42. Levine EA, Trippon M, Das Gupta TK. Preoperative multimodality treatment for soft tissue sarcomas. Cancer. 1993; 71:3685-3689.
43. Creech O, Krementz E, Ryan R. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958; 148:616-632.
44. Krementz ET, Carter RD, Sutherland CM, et al. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg. 1977; 185:555-564.
45. McBride CM. Sarcomas of the limbs. Results of adjuvant chemotherapy using isolation perfusion. Arch Surg. 1974; 109:304-308.
46. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, et al. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer. 1987; 60:1703-1707.
47. Lehti PM, Moseley HS, Janoff K, et al. Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet. 1986; 162:149-152.
48. Klaase JM, Kroon BB, Benckhuijsen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer. 1989; 64:616-621.
49. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer. 1994; 73:2140-2146.
50. Di Filippo F, Calabro AM, Cavallari A, et al. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg. 1988; 12:332-339.
51. Lejeune F, Lienard D, Eggermont A, et al. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ Shock. 1994; 43:191-197.
52. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992; 10:52-60.
53. Benckhuijsen C, Kroon BB, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol. 1988; 14:157-163.
54. Herman TS. Temperature dependence of Adriamycin, cis-diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res. 1983; 43:517-520.
55. Bates DA, Mackillop WJ. The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br J Cancer. 1990; 62:183-188.
56. Watanabe N, Niitsu Y, Umeno H, et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res. 1988; 48:650-653.
57. Blair SL, Lewis JJ, Leung D, et al. Multifocal extremity sarcoma: an uncommon and controversial entity. Ann Surg Oncol. 1998; 5:37-40.
58. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975; 72:3666-3670.
59. Pfreundschuh MG, Steinmetz HT, Tuschen R, et al. Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur J Cancer Clin Oncol. 1989; 25:379-388.
60. Thomson A. The cytokine handbook, 3d ed. Academic Press, 1998.
61. Plaat BE, Molenaar WM, Mastik MF, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin Cancer Res. 1999; 5:1650-1657.
62. Nobuhara M, Kanamori T, Ashida Y, et al. The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor. Jpn J Cancer Res. 1987; 78:193-201.
63. Asami T, Imai M, Tanaka Y, et al. in vivo antitumor mechanism of natural human tumor necrosis factor involving a T cell-mediated immunological route. Jpn J Cancer Res. 1989; 80:1161-164.
64. Stoelcker B, Ruhland B, Hehlgans T, et al. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol. 2000; 156:1171-1176.
65. Naredi PL, Lindner PG, Holmberg SB, et al. The effects of tumour necrosis factor alpha on the vascular bed and blood flow in an experimental rat hepatoma. Int J Cancer. 1993; 54:645-649.
66. Isaka T, Maruno M, Muhammad AK, et al. Ultrastructural changes of the vascular endothelium after intra-arterial administration of tumor necrosis factor-alpha (TNF-alpha) in rat gliomas. J Neurooncol. 2000; 46:145-150.
67. Nooijen PT, Manusama ER, Eggermont AM, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer. 1996; 74:1908-1915.
68. Ruegg C, Dormond O, Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium. 2002; 9:151-160.
69. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer. 2000; 82:1000-1003.
70. van der Veen AH, de Wilt JH, Eggermont AM, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer. 2000; 82:973-980.
71. Manusama ER, Nooijen PT, Stavast J, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg. 1996; 83:551-555.
72. Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001; 61:1645-1651.
73. Vrouenraets BC, Klaase JM, Nieweg OE, et al. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. 1998; 14:224-31.
74. Rossi CR, Foletto M, Di Filippo F, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer. 1999; 86:1742-1749.
75. Robins HI, d'Oleire F, Kutz M, et al. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia. Cancer Lett. 1995; 89:55-62.
76. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and Adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA. 1975; 72:937-940.
77. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982; 18:905-910.
78. Allen RE Jr. Systemic leakage and side effects of tumor necrosis factor alpha administration via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg. 1996; 131:220.
79. van Ginkel RJ, Limburg PC, Piers DA, et al. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol. 2002; 9:355-363.
80. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13:1537-1545.
81. Bonifati DM, Ori C, Rossi CR, et al. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol. 2000; 46:517-522.
82. Seynhaeve AL, de Wilt JH, van Tiel ST, et al. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer. 2002; 86:1174-1179.
83. Lee YJ, Hou Z, Curetty L, et al. Synergistic effects of cytokine and hyperthermia on cytotoxicity in HT-29 cells are not mediated by alteration of induced protein levels. J Cell Physiol. 1993; 155:27-35.
84. Eggermont AM, Schraffordt Koops H, Lienard D. et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996; 14:2653-2665.
85. Marvin MR, Libutti SK, Kayton M, et al. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res. 1996; 63:248-255.
86. van der Veen AH, Eggermont AM, Seynhaeve AL, et al. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer. 1998; 77:901-906.
87. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas—rationale for combination with radiotherapy. Acta Oncol. 2000; 39:207-211.
88. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997; 54:15-21.
89. Lans TE, Ten Hagen TL, Van Horssen R, et al. Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma. Ann Surg Oncol. 2002; 9:812-819.
90. Ten Hagen TL, Van Der Veen AH, Nooijen PT, et al. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer. 2000; 87:829-837.
91. Needham D, Anyarambhatla G, Kong G, et al. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000; 60:1197-1201.
92. Olieman AF, van Ginkel RJ, Molenaar WM, et al. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? Arch Orthop Trauma Surg. 1998; 118:70-74.
93. Lev-Chelouche D, Abu-Abeid S, Kollander Y, et al. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol. 1999; 70:185-189.
94. Bickels J, Manusama ER, Gutman M, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol. 1999; 25:509-514.
95. Lev-Chelouche D, Abu-Abeid S, Nakache R, et al. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Surgery. 1999; 126:963-967.
96. Lev-Chelouche D, Abu-Abeid S, Merimsky O, et al. Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. Arch Surg. 1999; 134:177-180.
97. Catton C, Davis A, Bell R, et al. Soft tissue sarcoma of the extremity. Limb salvage after failure of combined conservative therapy. Radiother Oncol. 1996; 41:209-214.
98. Vrouenraets BC, Keus RB, Nieweg OE, et al. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/− interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol. 1997; 65:88-94.
99. Olieman AF, Pras E, van Ginkel RJ, et al. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 1998; 40:807-814.
100. Issakov J, Merimsky O, Gutman M, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol. 2000; 7:155-159.
101. van Ginkel RJ, Kole AC, Nieweg OE, et al. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med. 1999; 40:262-267.
102. Kettelhack C, Wickede M, Vogl T, et al. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors. Cancer. 2002; 94:1557-1564.
103. Hill S, Fawcett WJ, Sheldon J, et al. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg. 1993; 80:995-997.
104. Santinami M, Deraco M, Azzarelli A, et al. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Tumori. 1996; 82:579-584.
105. Olieman AF, van Ginkel RJ, Hoekstra HJ, et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol. 1997; 4:64-69.
106. Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000; 26:669-678.
107. Pezzi CM, Pollock RE, Evans HL, et al. Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg. 1990; 211:476-481.
108. Klicks RJ, Vrouenraets BC, Nieweg OE, et al. Vascular complications of isolated limb perfusion. Eur J Surg Oncol. 1998; 24:288-291.
109. Zwaveling JH, Maring JK, Clarke FL, et al. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med. 1996; 24:765-770.
110. Stam TC, Swaak AJ, de Vries MR, et al. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol. 2000; 7:268-275.
111. Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion—comparison between the effects of perfusion with rhTNF alpha and a “triple-drug” regimen. Eur J Cancer. 1997; 33:596-601.
112. Jimenez RE, Zalupski MM, Frank JJ, et al. Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy. Cancer. 1999; 86:976-981.
113. Nakanishi H, Myoui A, Ochi T, et al. P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol. 1997; 123:352-356.
114. Hoffmann J, Schmidt-Peter P, Hansch W, et al. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res. 1999; 5:2198-2204.
115. Abolhoda A, Wilson AE, Ross H, et al. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res. 1999; 5:3352-3356.
116. Levine EA, Holzmayer T, Bacus S, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol. 1997; 15:3249-3257.
117. Komdeur R, Plaat BE, Hoekstra HJ, et al. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer. 2001; 91:1940-1948.
118. Decoster E, Vandevoorde V, Beyaert R, et al. Resistance to tumor necrosis factor (TNF) cytotoxicity by autocrine TNF production is independent of intracellular signaling pathways. FEBS Lett. 1997; 416:183-186.
119. Decoster E, Cornelis S, Vanhaesebroeck B, et al. Autocrine tumor necrosis factor (TNF) and lymphotoxin (LT) alpha differentially modulate cellular sensitivity to TNF/LT-alpha cytotoxicity in L929 cells. J Cell Biol. 1998; 143:2057-2065.
120. Selinsky CL, Boroughs KL, Halsey Jr, WA et al. Multifaceted inhibition of anti-tumour immune mechanisms by soluble tumour necrosis factor receptor type I. Immunology. 1998; 94:88-93.
121. Jaattela M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int J Cancer. 1995; 60:689-693.